Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01857271 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01857271 is a Phase 2 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 3 participants.
The verdict
NCT01857271, a Phase 2 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well erlotinib hydrochloride works before surgery in treating patients with stage III non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Therapeutic Conventional Surgery
- DRUG Erlotinib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-11 |
| Est. Completion | 2017-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01857271
The ClinicalTrials.gov registry entry for NCT01857271 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01857271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01857271 about?
NCT01857271 is a clinical study titled "Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer". This phase II trial studies how well erlotinib hydrochloride works before surgery in treating patients with stage III non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before s...
What is the current status of trial NCT01857271?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2013-11. Estimated completion is 2017-08-31.
What interventions are being tested in trial NCT01857271?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Erlotinib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01857271?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.